Staphylococcus aureus alpha-toxin is conserved among diverse hospital respiratory isolates collected from a global surveillance study and is neutralized by monoclonal antibody MEDI4893

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 9, 2016, Pages 5312-5321

  Tabor, David E ^a   Yu, Li ^a   Mok, Hoyin ^a   Tkaczyk, Christine ^a   Sellman, Bret R ^a   Wu, Yuling ^a   Oganesyan, Vaheh ^a   Slidel, Tim ^a   Jafri, Hasan ^a   McCarthy, Michael ^a   Bradford, Patricia ^b   Esser, Mark T ^a  

^a MEDIMMUNE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; EPITOPE; HEMOLYSIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MEDI 4893; STAPHYLOCOCCUS ALPHA TOXIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BACTERIAL TOXIN; NEUTRALIZING ANTIBODY; STAPHYLOCOCCAL ALPHA-TOXIN; SUVRATOXUMAB;

ADOLESCENT; ADULT; AFRICA; AGED; ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; AUSTRALIA; BACTERIAL GENE; BACTERIUM ISOLATE; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHUS BIOPSY; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; ERYTHROCYTE; EUROPE; FEMALE; GENE SEQUENCE; HEMOLYSIS; HEMOLYSIS ASSAY; HUMAN; INFANT; INFECTION PREVENTION; LENGTH OF STAY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIDDLE EAST; MULTILOCUS SEQUENCE TYPING; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RESPIRATORY TRACT INFECTION; SOUTH AND CENTRAL AMERICA; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TRACHEAL ASPIRATION PROCEDURE; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA; AGE; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CONSERVED SEQUENCE; DNA SEQUENCE; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; GENETICS; GLOBAL HEALTH; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR MODEL; MUTATION; PATHOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; PRESCHOOL CHILD; PROTEIN CONFORMATION; STAPHYLOCOCCAL INFECTIONS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; CHILD; CHILD, PRESCHOOL; CONSERVED SEQUENCE; EPIDEMIOLOGICAL MONITORING; FEMALE; GLOBAL HEALTH; HEMOLYSIN PROTEINS; HUMANS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; PNEUMONIA, VENTILATOR-ASSOCIATED; PROTEIN CONFORMATION; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84983371981     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00357-16     Document Type: Article

References (45)

1. Pujol M, Pena C, Pallares R, Ariza J, Ayats J, Dominguez MA, Gudiol F. 1996. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 100:509-516. http://dx.doi.org/10.1016/S0002-9343(96)00014-9.
2. Mest DR, Wong DH, Shimoda KJ, Mulligan ME, Wilson SE. 1994. Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection. Anesth Analg 78:644-650.
3. Perl TM, Golub JE. 1998. New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S. aureus nasal carriage. Ann Pharmacother 32:S7-S16. http://dx.doi.org/10.1177/106002809803200104.
4. von Eiff C, Becker K, Machka K, Stammer H, Peters G. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 344:11-16. http://dx.doi.org/10.1056/NEJM200101043440102.
5. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team, Participating NHSN Facilities. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1-14. http://dx.doi.org/10.1086/668770.
6. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. 2012. Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med 6:533-555. http://dx.doi.org/10.1586/ers.12.45.
7. Otto M. 2014. Staphylococcus aureus toxins. Curr Opin Microbiol 17:32-37. http://dx.doi.org/10.1016/j.mib.2013.11.004.
8. Alonzo F III, Torres VJ. 2014. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol Mol Biol Rev 78:199-230. http://dx.doi.org/10.1128/MMBR.00055-13.
9. Rooijakkers SH, Ruyken M, van Roon J, van Kessel KP, van Strijp JA, van Wamel WJ. 2006. Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell Microbiol 8:1282-1293. http://dx.doi.org/10.1111/j.1462-5822.2006.00709.x.
10. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus alphatoxin: nearly a century of intrigue. Toxins (Basel) 5:1140-1166. http://dx.doi.org/10.3390/toxins5061140.
11. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13:1405-1406. http://dx.doi.org/10.1038/nm1207-1405.
12. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, Ting JP, Duncan JA. 2009. Staphylococcus aureus alphahemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 4:e7446. http://dx.doi.org/10.1371/journal.pone.0007446.
13. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alphahemolysin. J Infect Dis 206:352-356. http://dx.doi.org/10.1093/infdis/jis192.
14. Tamber S, Reyes D, Donegan NP, Schwartzman JD, Cheung AL, Memmi G. 2010. The staphylococcus-specific gene rsr represses agr and virulence in Staphylococcus aureus. Infect Immun 78:4384-4391. http://dx.doi.org/10.1128/IAI.00401-10.
15. Tamber S, Cheung AL. 2009. SarZ promotes the expression of virulence factors and represses biofilm formation by modulating SarA and agr in Staphylococcus aureus. Infect Immun 77:419-428. http://dx.doi.org/10.1128/IAI.00859-08.
16. Montgomery CP, Boyle-Vavra S, Daum RS. 2010. Importance of the global regulators Agr and SaeRS in the pathogenesis of CA-MRSA USA300 infection. PLoS One 5:e15177. http://dx.doi.org/10.1371/journal.pone.0015177.
17. Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, Stover CK, Sellman BR. 2015. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. mBio 6:e02272-14. http://dx.doi.org/10.1128/mBio.02272-14.
18. Tkaczyk C, Hamilton MM, Datta V, Yang XP, Hilliard JJ, Stephens GL, Sadowska A, Hua L, O'Day T, Suzich J, Stover CK, Sellman BR. 2013. Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS One 8:e75103. http://dx.doi.org/10.1371/journal.pone.0075103.
19. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050-1058. http://dx.doi.org/10.1086/656043.
20. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19:377-385. http://dx.doi.org/10.1128/CVI.05589-11.
21. Ragle BE, Bubeck Wardenburg J. 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77:2712-2718. http://dx.doi.org/10.1128/IAI.00115-09.
22. Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. 2012. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 206: 915-923. http://dx.doi.org/10.1093/infdis/jis462.
23. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 56:1554-1561. http://dx.doi.org/10.1093/cid/cit123.
24. Ruotsalainen E, Karden-Lilja M, Kuusela P, Vuopio-Varkila J, Virolainen-Julkunen A, Sarna S, Valtonen V, Jarvinen A. 2008. Methicillinsensitive Staphylococcus aureus bacteraemia and endocarditis among injection drug users and nonaddicts: host factors, microbiological and serological characteristics. J Infect 56:249-256. http://dx.doi.org/10.1016/j.jinf.2008.01.009.
25. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:1108-1117. http://dx.doi.org/10.1128/AAC.02190-13.
26. Ohlsen K, Lorenz U. 2010. Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol 300:402-410. http://dx.doi.org/10.1016/j.ijmm.2010.04.015.
27. MedImmune. 2015. Study of the efficacy and safety of MEDI4893 (SAATELLITE). https://clinicaltrials.gov/ct2/show/NCT02296320.
28. Cohen TS, Hilliard JJ, Jones-Nelson O, Keller AE, O'Day T, Tkaczyk C, DiGiandomenico A, Hamilton M, Pelletier M, Wang Q, Diep BA, Le VT, Cheng L, Suzich J, Stover CK, Sellman BR. 2016. Staphylococcus aureus alpha toxin potentiates opportunistic bacterial lung infections. Sci Transl Med 8:329ra331. http://dx.doi.org/10.1126/scitranslmed.aad9922.
29. Hua L, Cohen TS, Shi Y, Datta V, Hilliard JJ, Tkaczyk C, Suzich J, Stover CK, Sellman BR. 2015. MEDI4893∗ promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother 59: 4526-4532. http://dx.doi.org/10.1128/AAC.00510-15.
30. Sharma-Kuinkel BK, Wu Y, Tabor DE, Mok H, Sellman BR, Jenkins A, Yu L, Jafri HS, Rude TH, Ruffin F, Schell WA, Park LP, Yan Q, Thaden JT, Messina JA, Fowler VG, Jr, Esser MT. 2015. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol 53:227-236. http://dx.doi.org/10.1128/JCM.02023-14.
31. Ewing B, Hillier L, Wendl MC, Green P. 1998. Base-calling of automated sequencer traces using Phred. I. Accuracy assessment. Genome Res 8:175-185.
32. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
33. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-425.
34. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, Sensabaugh GF, Perdreau-Remington F. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367:731-739. http://dx.doi.org/10.1016/S0140-6736(06)68231-7.
35. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. 2014. Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem 289: 29874-29880. http://dx.doi.org/10.1074/jbc.M114.601328.
36. Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, Gouaux JE. 1996. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 274:1859-1866. http://dx.doi.org/10.1126/science.274.5294.1859.
37. Cheung GY, Duong AC, Otto M. 2012. Direct and synergistic hemolysis caused by Staphylococcus phenol-soluble modulins: implications for diagnosis and pathogenesis. Microbes Infect 14:380-386. http://dx.doi.org/10.1016/j.micinf.2011.11.013.
38. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, DeLeo FR, Otto M. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13:1510-1514. http://dx.doi.org/10.1038/nm1656.
39. Monecke S, Muller E, Buchler J, Stieber B, Ehricht R. 2014. Staphylococcus aureus in vitro secretion of alpha toxin (hla) correlates with the affiliation to clonal complexes. PLoS One 9:e100427. http://dx.doi.org/10.1371/journal.pone.0100427.
40. Tavares A, Nielsen JB, Boye K, Rohde S, Paulo AC, Westh H, Schonning K, de Lencastre H, Miragaia M. 2014. Insights into alpha-hemolysin (Hla) evolution and expression among Staphylococcus aureus clones with hospital and community origin. PLoS One 9:e98634. http://dx.doi.org/10.1371/journal.pone.0098634.
41. Stulik L, Malafa S, Hudcova J, Rouha H, Henics BZ, Craven DE, Sonnevend AM, Nagy E. 2014. alpha-hemolysin activity of methicillin-susceptible Staphylococcus aureus predicts ventilator-associated pneumonia. Am J Respir Crit Care Med 190:1139-1148. http://dx.doi.org/10.1164/rccm.201406-1012OC.
42. Novick RP, Geisinger E. 2008. Quorum sensing in staphylococci. Annu Rev Genet 42:541-564. http://dx.doi.org/10.1146/annurev.genet.42.110807.091640.
43. Thoendel M, Kavanaugh JS, Flack CE, Horswill AR. 2011. Peptide signaling in the staphylococci. Chem Rev 111:117-151. http://dx.doi.org/10.1021/cr100370n.
44. O'Reilly M, Kreiswirth B, Foster TJ. 1990. Cryptic alpha-toxin gene in toxic shock syndrome and septicaemia strains of Staphylococcus aureus. Mol Microbiol 4:1947-1955. http://dx.doi.org/10.1111/j.1365-2958.1990.tb02044.x.
45. McGavin MJ, Arsic B, Nickerson NN. 2012. Evolutionary blueprint for host- and niche-adaptation in Staphylococcus aureus clonal complex CC30. Front Cell Infect Microbiol 2:48. http://dx.doi.org/10.3389/fcimb.2012.00048.